Department of Surgery, CUHK

Dr XU Mingjing Iris    

Research Assistant Professor

mxuadd this for spam@add this for


Dr. Xu is a Research Assistant Professor in Department of Surgery at The Chinese University of Hong Kong. She completed her PhD study in Department of Pathology, The University of Hong Kong in 2016 and received her postdoc training in Princess Margaret Cancer Centre, Canada.

Her research work focuses on the molecular pathogenesis of hepatocellular carcinoma (HCC). Using multidisciplinary approaches, Dr. Xu and her colleagues aim to developing new therapeutic strategies for HCC by targeting abberant alternative splicing events in HCC.

Research Interests

  • Investigation of aberrant alternative splicing event in liver cancer
  • Biochemical and functional characterization of metabolic genes in liver cancer

Additional Information

Awards and Honors:

  • Lady Tata Fellowship
    The Lady Tata Memorial Fund, 2018-2019
  • Princess Margaret Postdoctoral Fellowship
    Princess Margaret Cancer Centre, Toronto, Canada, 2017-2018
  • Chan To Haan Prize for Research Postgraduate Students in Pathology
    The University of Hong Kong, 2016-2017
  • Yu To Sang and Yu Shing Keung Memorial Fund Scholarship
    The University of Hong Kong, 2016
  • Best Presentation Award in Plenary Session
    The Liver Week, Korea
    The Korean Association for the Study of the Liver, 2015
  • Outstanding Oral Presentation Award
    Hong Kong Inter-University Postgraduate Symposium, 2015
  • YS and Christabel Lung Postgraduate Scholarship
    Li Ka Shing Faculty of Medicine, The University of Hong Kong, 2015
  • Young Investigator Award
    21st Hong Kong International Cancer Congress, 2014

Selected Publications

  1. J.B. Lee, D.H. Khan, R. Hurren, M.J. Xu, Y. Na, H. Kang, S. Mirali, X.M. Wang, M.V. Gronda, Y. Jitkova, N. MacLean, A. Arruda, Z. Alaniz, M.Y. Konopleva, M. Andreeff, M.D. Minden, L. Zhang, A.D Schimmer. Venetoclax enhances T cell-mediated anti-leukemic activity by increasing ROS production. Blood 2021.
  2. A. Seneviratne, M.J. Xu (co-first author), J. A Henao, V.A. Fajardo, Z. Hao, V. Voisin, G.W. Xu, R. Hurren, S. Kim, N. MacLean, X.M. Wang, M. Gronda, D. Jeyaraju, Y. Jitkova, T. Ketela, M. Mullokandov, D. Sharon, G.T. Thomas, R. Chouinard-Watkins, J.R. Hawley, C. Schafer, H.L. Yau, Z. Khuchua, A. Aman, R. Al-awar, A. Gross, S.M. Claypool, R. Bazinet, M. Lupien, S. Chan, D.D. Carvalho, M.D. Minden, G.D. Bader, K.D. Stark, P. LeBlanc, and A.D. Schimmer. The mitochondrial transacylase, Tafazzin, regulates AML stemness and differentiation by modulating intracellular levels of phospholipids. Cell Stem Cell 24(4):621-636, 2019.
  3. D. Lee, M.J. Xu, D.K. Chiu, J Leibold, A.P. Tse, M.H. Bao, V.W. Yuen, C.Y. Chan, R.K. Lai , D.W. Chin, D.F. Chan, T.T. Cheung, S.H. Chok, C.M. Wong, S.W. Lowe, I.O. Ng, and C.C. Wong. Induction of oxidative stress via inhibition of thioredoxin reductase 1 is an effective therapeutic approach for hepatocellular carcinoma. Hepatology 69(4):1768-1786, 2018.
  4. D. Lee, M.J. Xu (co-first author), D.K. Chiu, R.K. Lai, A.P. Tse, L.L. Li, C.T. Law, F.H. Tsang, L.L. Wei, C.M. Wong, I.O. Ng, and C.C. Wong. Methylenetetrahydrofolate dehydrogenase 1-like (MTHFD1L) of the folate cycle confers cancer cell metabolic and growth advantages. Journal of Clinical Investigation 1;127(5):1856-1872, 2017.
  5. M.J. Xu, R.K. Lai, S.H. Lin, A.P. Tse, D.K. Chiu, H.Y. Koh, C.T. Law, C.M. Wong, Z.W. Cai, C.C. Wong, and I.O. Ng. Transketolase counteracts oxidative stress to drive cancer development. Proceedings of the National Academy of Sciences of the United States of America 113, E725-734, 2016.
  6. D.W. Ho, L.K. Chan, Y.T. Chiu, M.J. Xu, R.T. Poon, T.T. Cheung, C.N. Tang, V.W. Tang, I.L. Lo, P.W. Lam, D.T. Yau, M.X. Li, C.M. Wong, and I.O. Ng. TSC1/2 mutations define a molecular subset of HCC with aggressive behavior and treatment implication. Gut 66(8):1496-1506, 2017.
  7. D. K. Chiu, M.J. Xu, R.K. Lai, A.P. Tse, L.L. Wei, H.Y. Koh, L.L. Li, D. Lee, R.C. Lo, C.M. Wong, I.O. Ng, and C.C. Wong. Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26. Hepatology 64(3):797-813, 2016.
  8. R.K. Lai, M.J. Xu, D.K. Chiu, A.P. Tse, L.L. Wei, C.T. Law, D. Lee, C.M. Wong, M. P. Wong, I.O. Ng, and C.C. Wong. NDUFA4L2 fine-tunes oxidative stress in hepatocellular carcinoma. Clinical Cancer Research 22, 3105-3117, 2016.

Copyright © 2024. All Rights Reserved. Department of Surgery, The Chinese University of Hong KongCUHK

C O N T A C T   U S